Chapter title |
Stroke: Basic and Clinical
|
---|---|
Chapter number | 10 |
Book title |
Neurodegenerative Diseases
|
Published in |
Advances in neurobiology, July 2017
|
DOI | 10.1007/978-3-319-57193-5_10 |
Pubmed ID | |
Book ISBNs |
978-3-31-957191-1, 978-3-31-957193-5
|
Authors |
Tarvinder P. Singh, Jonathan R. Weinstein, Sean P. Murphy, Singh, Tarvinder P., Weinstein, Jonathan R., Murphy, Sean P. |
Abstract |
Tissue plasminogen activator (tPA) was first approved in the USA 25 years ago for those who had experienced a recent occlusion (<3 h) of a cerebral vessel. Now, advances in clot retrieval (stentriever), in concert with tPA, heralds new optimism for ischemic stroke victims, but adds more pressure to identify therapies that will minimize hypoxic damage, protect compromised cells, and promote rehabilitation. In the past preclinical investigations have been poor at predicting potential clinical therapy, but they have contributed enormously to understanding post-stroke pathology. Current clinical trials ( www.strokecenter.org/trials ) anticipate a broad range of approaches: from hypothermia, to cell therapy, to neuroprotection. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 2 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 40 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 5 | 13% |
Student > Ph. D. Student | 5 | 13% |
Other | 4 | 10% |
Student > Doctoral Student | 3 | 8% |
Student > Master | 2 | 5% |
Other | 4 | 10% |
Unknown | 17 | 43% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 10 | 25% |
Neuroscience | 3 | 8% |
Nursing and Health Professions | 2 | 5% |
Agricultural and Biological Sciences | 1 | 3% |
Social Sciences | 1 | 3% |
Other | 3 | 8% |
Unknown | 20 | 50% |